What Drumetix does

Drumetix Laboratories, LLC is a pharmaceutical contract research organization (CRO) headquartered in Greensboro, North Carolina, providing in vitro and in vivo DMPK, bioanalytical, and protein characterization services to pharmaceutical, biotechnology, and academic clients. Its core offering spans ADME assays (permeability, plasma stability, protein binding, metabolic stability, CYP inhibition, glutathione conjugation), small molecule biomarker analysis (neurotransmitters, atRA, creatinine, desmosine), metabolite identification, GLP and non-GLP bioanalysis, analytical method development, stability testing, and biotherapeutic protein characterization including ADC DAR determination. The laboratory operates Sciex triple quadrupole mass spectrometers for quantitative LC-MS/MS work and a Bruker maXis II QTof with high resolution, high mass accuracy, and electron transfer dissociation (ETD) for advanced protein and metabolite characterization.

The business operates on a fee-for-service, project-based contract research model. Pricing is not publicly disclosed and is expected to vary by study design, sample count, assay type, and regulatory tier (GLP vs non-GLP). Go-to-market is direct B2B sales to pharmaceutical and biotech companies and academic institutions; in vivo PK studies are delivered through partner cooperation rather than in-house vivarium capability, allowing the lab to focus capital on mass spectrometry infrastructure. Distribution is global in scope but executed from a single US site. The company is privately held with no disclosed institutional funding or parent entity.

Drumetix competes on scientific depth in drug metabolism and mass spectrometry, instrument capability breadth (notably ETD-enabled protein work), and dual-track GLP/non-GLP turnaround flexibility. Its service menu has expanded from small-molecule DMPK into biotherapeutics characterization and environmental cyanotoxin analysis, suggesting deliberate platform broadening within an otherwise niche CRO footprint.

Name

Drumetix

Legal name

Drumetix Laboratories, LLC

Website

https://drumetix.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Drumetix Laboratories is a pharmaceutical contract research organization (CRO) providing in vitro and in vivo DMPK, bioanalytical, and protein characterization services on LC-MS/MS platforms to pharmaceutical, biotech, academic, and environmental clients from its Greensboro, NC laboratory.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Research Services (DMPK/Bioanalytical CRO)

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

DMPK / ADME & Bioanalysis (HLAGAFAC)

akta.pro secondary industries

Bioanalytical & PK/PD Sample Analysis (Trial Support) (HLAGAEAG), Small-Molecule Analytical Development & Method Validation (CMC) (HLAGAHAF), Metabolomics & Lipidomics Services (HLAGANAG)

Keywords

• Pharmaceutical CRO services
• Drug metabolism pharmacokinetics
• Bioanalytical LC-MS/MS
• ADME assay services
• Protein characterization CRO

Headquarters

HQ city

Greensboro

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: Fee-for-service contract research organization providing DMPK, bioanalytical, and protein characterization services to pharmaceutical companies and academic institutions. Revenue generated through project-based contracts for drug metabolism studies, bioanalysis, stability testing, and other analytical services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Drumetix Laboratories is a pharmaceutical contract research organization that provides in vitro and in vivo DMPK (drug metabolism and pharmacokinetics) services, bioanalytical support, small molecule biomarker analysis, stability testing, and LC/MS-based protein characterization for drug discovery and preclinical/clinical development. Services are delivered from its Greensboro, North Carolina laboratory using LC-MS/MS instrumentation including Sciex triple quadrupole and Bruker maXis II QTof platforms, supporting both rapid-turnaround non-GLP discovery studies and GLP-compliant regulatory work.

Product overview

Drumetix Laboratories is a pharmaceutical contract research organization (CRO) providing comprehensive drug metabolism and pharmacokinetics (DMPK) and bioanalytical services. The company offers an integrated portfolio of services organized around core capabilities: In Vitro DMPK (ADME) assays including permeability, plasma stability, protein binding, metabolic stability, CYP inhibition, and glutathione conjugation testing; Small Molecule Biomarkers analysis using LC-MS/MS for neurotransmitters, retinoids, and creatinine; Bioanalytical Services encompassing metabolite identification, non-GLP and GLP bioanalysis, and method development and validation; Analytical Services for API characterization and impurity analysis; Stability Testing for drug substances and products; and Biological Services for protein characterization, biotherapeutics bioanalysis, and protein biomarker quantification. The laboratory is equipped with Sciex triple quadrupole instruments and a Bruker maXis II QTof instrument with high resolution, high mass accuracy, and electron transfer dissociation (ETD) capabilities. Services are provided for both discovery and preclinical/clinical development stages.

Differentiator

Problem solved

Functional benefit

Products and services

• In Vitro DMPK (ADME) Services

Quantifiable outcome

• Quick turnaround DMPK assays and non-GLP bioanalysis for PK screening and candidate selection
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• In Vivo PK Study PartnerscoreOthersDrumetix provides in vivo PK studies (in-life) through cooperation with partners. This partnership enables the laboratory to offer comprehensive DMPK services including in vivo studies alongside their in vitro capabilities and bioanalytical services.

Expansion highlights3 records

Direct peers

• Celerion: Celerion is a clinical pharmacology and early-phase CRO offering bioanalytical, ADME, and DMPK services to pharma and biotech. It is highly comparable to Drumetix in service mix (LC-MS/MS bioanalysis, ADME assays, biomarker analysis) and target customers, though it operates at a larger scale.
• Pyxant Labs: Pyxant Labs (formerly PBI International) is a bioanalytical CRO specializing in LC-MS/MS small-molecule and biomarker analysis for pharmaceutical and academic clients. Directly comparable to Drumetix in boutique bioanalytical CRO positioning and scientific service scope.
• Bioanalytical Systems, Inc. (BASi): BASi is a CRO providing bioanalytical, DMPK, and drug discovery services including LC-MS/MS sample analysis and contract research. Directly comparable to Drumetix as a small/mid-size specialty bioanalytical CRO serving pharma and academic customers.
• Frontage Laboratories: Frontage Laboratories provides bioanalytical, CMC, and DMPK services to pharma and biotech, including LC-MS/MS method development and validation. Comparable in service scope (GLP bioanalysis, DMPK, biomarkers), though Frontage operates at significantly larger scale.
• Absorption Systems: Absorption Systems (now part of Eurofins) is a specialty CRO focused on ADME/DMPK, permeability, and pharmacokinetic studies using in vitro and in vivo models. Directly comparable to Drumetix's core in vitro DMPK and PAMPA-style permeability offerings for pharmaceutical discovery programs.
• Sekisui Xenotech (formerly XenoTech): Sekisui Xenotech provides in vitro ADME services including metabolic stability, CYP reaction phenotyping, and protein binding using hepatic models. Closely comparable to Drumetix's metabolic stability, CYP inhibition, and protein binding assay portfolio serving pharma DMPK programs.

Broad incumbents

• Eurofins Scientific: Eurofins is a global testing group with a sizable bioanalytical and pharmaceutical services footprint, including DMPK, ADME, and biomarker capabilities. It competes broadly with Drumetix for outsourced bioanalytical work and has acquired specialty DMPK firms (e.g., Absorption Systems).
• Charles River Laboratories: Charles River is a global CRO with extensive DMPK, safety assessment, and bioanalytical services. It is a broad incumbent competing with Drumetix for pharma DMPK outsourcing at much larger scale and global footprint.
• Labcorp Drug Development (formerly Covance): Labcorp Drug Development is a leading global CRO offering bioanalytical, ADME, and clinical pharmacology services. A broad incumbent directly competing with Drumetix for outsourced LC-MS/MS bioanalysis and DMPK projects.
• WuXi AppTec: WuXi AppTec is a large global CRO/CDMO providing DMPK, bioanalytical, and drug discovery services. A broad incumbent that competes with Drumetix for outsourced DMPK and bioanalysis, particularly from biopharma sponsors.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/drumetix-laboratories-llc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Drumetix